9.27
6.80%
+0.59
IGM Biosciences Inc stock is currently priced at $9.27, with a 24-hour trading volume of 264.83K.
It has seen a +6.80% increased in the last 24 hours and a -34.76% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $8.66 pivot point. If it approaches the $9.54 resistance level, significant changes may occur.
IGM Biosciences Inc Stock (IGMS) Financials Data
IGM Biosciences Inc (IGMS) Revenue 2023
IGMS reported a revenue (TTM) of $2.13 million for the quarter ending December 31, 2023.
IGM Biosciences Inc (IGMS) Net Income 2023
IGMS net income (TTM) was -$246.42 million for the quarter ending December 31, 2023, a -11.45% decrease year-over-year.
IGM Biosciences Inc (IGMS) Cash Flow 2023
IGMS recorded a free cash flow (TTM) of -$204.61 million for the quarter ending December 31, 2023, a -1,174% decrease year-over-year.
IGM Biosciences Inc (IGMS) Earnings per Share 2023
IGMS earnings per share (TTM) was -$4.78 for the quarter ending December 31, 2023, a +10.99% growth year-over-year.
IGM Biosciences Inc Stock (IGMS) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Schwarzer Fred | CEO AND PRESIDENT |
Mar 14 '24 |
Sale |
10.17 |
4,182 |
42,533 |
216,651 |
Tahir Misbah | CHIEF FINANCIAL OFFICER |
Mar 14 '24 |
Sale |
10.17 |
2,543 |
25,864 |
90,418 |
Takimoto Chris H | CHIEF MEDICAL OFFICER |
Mar 14 '24 |
Sale |
10.17 |
2,535 |
25,782 |
94,388 |
Keyt Bruce | CHIEF SCIENTIFIC OFFICER |
Mar 14 '24 |
Sale |
10.17 |
1,844 |
18,754 |
171,856 |
Decker Lisa Lynn | CHIEF BUSINESS OFFICER |
Mar 14 '24 |
Sale |
10.17 |
1,578 |
16,049 |
61,006 |
Weber Steven | PRINCIPAL ACCOUNTING OFFICER |
Mar 14 '24 |
Sale |
10.17 |
464 |
4,719 |
26,507 |
Schwarzer Fred | CEO AND PRESIDENT |
Mar 13 '24 |
Sale |
9.88 |
4,765 |
47,055 |
220,833 |
Tahir Misbah | CHIEF FINANCIAL OFFICER |
Mar 13 '24 |
Sale |
9.88 |
2,897 |
28,608 |
92,961 |
Takimoto Chris H | CHIEF MEDICAL OFFICER |
Mar 13 '24 |
Sale |
9.88 |
2,889 |
28,529 |
96,923 |
Keyt Bruce | CHIEF SCIENTIFIC OFFICER |
Mar 13 '24 |
Sale |
9.88 |
2,101 |
20,748 |
173,700 |
IGM Biosciences Inc Stock (IGMS) Latest News
Where IGM Biosciences Stands With Analysts
Benzinga
IGM Biosciences, Inc. (IGMS) Reports Q4 Loss, Lags Revenue Estimates
Zacks Investment Research
IGM Biosciences Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
GlobeNewswire Inc.
Wall Street Analysts Think IGM Biosciences, Inc. (IGMS) Could Surge 63.1%: Read This Before Placing a Bet
Zacks Investment Research
Strength Seen in iTeos Therapeutics, Inc. (ITOS): Can Its 7.4% Jump Turn into More Strength?
Zacks Investment Research
Wall Street Analysts Believe IGM Biosciences, Inc. (IGMS) Could Rally 35.08%: Here's is How to Trade
Zacks Investment Research
About IGM Biosciences Inc
IGM Biosciences, Inc., a biotechnology company, engages in the research and development of Immunoglobulin M (IgM) antibodies for the treatment of cancer. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 1 clinical trials to treat patients with B cell NHL and other B cell malignancies. It is also developing IGM-8444, an IgM antibody targeting Death Receptor 5 proteins; and IGM-7354, is a bispecific IgM antibody delivering interleukin-15 cytokines to PD-L1 expressing cells for use in the treatment of patients with solid and hematologic malignancies. IGM Biosciences, Inc. has a collaboration with Atreca Inc. and BeiGene Ltd. to discover, develop, and manufacture novel IgM and IgA antibodies targeting SARS-CoV-2 for the potential treatment of COVID-19. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
Cap:
|
Volume (24h):